- Mar 30, 2022
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS
- Mar 30, 2022
Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS
- Mar 30, 2022
What is Multiple Myeloma? www.uptodate.com
- Mar 30, 2022
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS
- Mar 29, 2022
Explore MCT: Join us in creating the most comprehensive platform for Myeloma Clinical Trials
- Mar 28, 2022
The Binding Site: Freelite Overview
- Mar 17, 2022
Patient Education: Elotuzumab (Empliciti) - Anti-SLAMF7 Monoclonal Antibody - Immunotherapy
- Mar 17, 2022
NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex
- Mar 16, 2022
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy
- Mar 15, 2022
Patient Education: Daratumumab & Daratumumab and Hyaluronidase-fihj - Monoclonal Ab - Immunotherapy
- Mar 14, 2022
Patient Education: Ciltacabtagene Autoleucel - Carvykti - (CART Cell Therapy) - Immunotherapy
- Mar 10, 2022
Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy
- Mar 9, 2022
NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant
- Mar 9, 2022
NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients
- Mar 2, 2022
What is a Myeloma Specialist Why do I Need one and How do I Find One? HealthTree University Myeloma
- Mar 2, 2022
NCT05228470: Phase 2: MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in China RRMM
- Mar 1, 2022
NCT05238311: Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
- Mar 1, 2022
Why is it important to become your own best advocate? HealthTree University Myeloma
- Mar 1, 2022
NCT05257083: Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT- NDMM CARTITUDE-6